Figure 2
Progression-free survival with dasatinib for the total treated population and for the imatinib-resistant CML-AP subgroup at 8 months' follow-up.

Progression-free survival with dasatinib for the total treated population and for the imatinib-resistant CML-AP subgroup at 8 months' follow-up.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal